ASX/Media Release
31 October 2016

ASX code: PIQ

Proteomics wins WA Exporter of the Year

Medical technology company Proteomics International Laboratories Ltd (ASX: PIQ) has edged out shipbuilding giant Austal and Fortescue Metals Group to win the WA Exporter of the Year Award.

The company also took out the Health and Biotechnology category of the WA Industry and Export Awards for the second year running for outstanding international success.

"It's fantastic to be recognised for our world-leading capabilities in delivering specialist analytical services, combined with our new innovations in medical technology," said PILL managing director Dr Richard Lipscombe.

"The awards highlight our growing export achievements in emerging markets, such as the Middle East, on top of our established strength across the Asian region."

PILL has seen significant growth in analytical services contracts in the past year, particularly in the massive Indian biotechnology market.

The company announced in August it had signed the first commercialisation deal for diabetic kidney disease test PromarkerD in the Dominican Republic and the US Territory of Puerto Rico, paving the way for expansion into other markets including the United States, China and Japan.

The WA Industry and Export Awards winners were announced on Friday evening, and PILL will now represent the State at the Australian Export Awards in Brisbane on November 24.

ENDS

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
www.proteomicsinternational.com

Susan Fitzpatrick-Napier [Media Contact]
Digital Mantra Group
T: +61 2 8218 2144
E: team@dmgpr.com

Greg Wood [Financial Advisor]
Managing Director
K S Capital
T: +61 416 076 377
E: g.wood@kscapital.com.au

About Proteomics International Laboratories (PILL)

PILL (ASX: PIQ) is a medical technology company focused on proteomics – the industrial scale study of the structure and function of proteins. In the last few years, proteins have become the drug class

of choice for the pharmaceutical industry because of their intimate role in biological systems. Thus proteomics technology is now playing a key role in understanding disease, from finding new diagnostic biomarkers to determining drug targets, and discovering new biopharmaceutical drugs.

PILL is recognised as a global leader in the field of proteomics. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia. The Company's business model uses its proprietary technology platform across three integrated areas, each massive growth markets:

1. **Diagnostics:** Biomarkers of disease and personalised medicine - focus on diabetic kidney disease.
   By 2020 the biomarkers market is estimated to double in size to $45.6 billion, and the personalised medicine market is forecast to be worth over $149 billion.
2. **Analytical services:** Specialist contract research fee-for-service model – focus on biosimilars QC.
   The global biosimilars market is expected to reach $6.2 billion by 2020, almost trebling from its 2015 level, as it seeks to replicate the multiple billion dollar blockbuster drugs that are coming off patent.
3. **Drug discovery:** Therapeutic peptide drug discovery - focus on painkillers and antibiotics.
   The global peptide therapeutics market is currently estimated to be worth $18 billion and is expected to increase at over 10% per year during 2016-2025.

In combination these areas offer, respectively, medium term products, near term cash flow, and blue sky potential by harnessing one complementary workflow centred on proteins.